FDA Approves Eli Lilly's Mounjaro To Reduce Cardiovascular Risk In Type 2 Diabetes
(RTTNews) - Eli Lilly and Co. (LLY), a pharmaceutical company, announced Friday that the U.S. Food and Drug Administration (FDA) approved Mounjaro (tirzepatide) to lower the risk of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal heart attack